Super-silencers are crucial for development and carcinogenesis in B cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40998810.
- Also identified by DOI 10.1038/s41467-025-63329-x and PMC identifier 12462470.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The strength of the repressive histone H3K27me3 signal varies across silencers. Focusing on regions with unusually strong signals-super-silencers-we show that B-cell super-silencers are initially linked to gene upregulation in development, with target genes highly expressed in stem cells. About 13% of B-cell super-silencers convert to super-enhancers in B-cell lymphoma; 22% of these recur in over half of patients. Genes like BCL6 and BACH2 tied to these conversions are downregulated faster by JQ1, a super-enhancer-disrupting anti-cancer agent. Super-silencers are enriched for B-cell cancer-associated variants-both somatic and germline-and translocation breakpoints, exceeding levels in other regulatory elements like CTCF binding sites. Over 80% of B-cell lymphoma t(3;14)(q27;q32) translocations fuse BCL6 super-silencers with enhancer-rich regions. Super-silencer repression depends on CpG content: CpG-rich elements block promoter-enhancer contacts; CpG-poor - inhibit looping. These findings highlight super-silencers' key role in B-cell regulation and suggest their alteration may be a primary factor of B-cell carcinogenesis.
Medical subject headings
- B-Lymphocytes
- Lymphoma, B-Cell
- Carcinogenesis